<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03230838</url>
  </required_header>
  <id_info>
    <org_study_id>7625A-034</org_study_id>
    <secondary_id>2016-004153-32</secondary_id>
    <nct_id>NCT03230838</nct_id>
  </id_info>
  <brief_title>MK-7625A Versus Meropenem in Pediatric Participants With Complicated Urinary Tract Infection (cUTI) (MK-7625A-034)</brief_title>
  <official_title>A Phase 2, Randomized, Active Comparator-Controlled, Multicenter, Double-Blind Clinical Trial to Study the Safety and Efficacy of Ceftolozane/Tazobactam (MK-7625A) Versus Meropenem in Pediatric Subjects With Complicated Urinary Tract Infection, Including Pyelonephritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the safety and tolerability of MK-7625A (ceftolozane/tazobactam)
      compared with that of meropenem in pediatric participants with cUTI, including
      pyelonephritis.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 26, 2018</start_date>
  <completion_date type="Anticipated">April 18, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 18, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events (AEs)</measure>
    <time_frame>Up to Day 49</time_frame>
    <description>Number of participants with one or more AEs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Discontinuations</measure>
    <time_frame>Up to Day 14</time_frame>
    <description>Number of participants who discontinued study drug due to an AE</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical response of cure</measure>
    <time_frame>Up to Test of Cure Visit (up to 23 days)</time_frame>
    <description>Percentage of participants who have a clinical response of cure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiological eradication of all baseline pathogens</measure>
    <time_frame>Up to Test of Cure Visit (up to 23 days)</time_frame>
    <description>Percentage of participants who have microbiological eradication or presumed eradication of all baseline pathogens.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Complicated Urinary Tract Infection</condition>
  <condition>Pyelonephritis</condition>
  <arm_group>
    <arm_group_label>Ceftolozane/Tazobactam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ceftolozane 20 mg/kg and tazobactam 10 mg/kg (maximum ceftolozane 1 g/dose and tazobactam 0.5 g/dose) administered intravenously (IV) every 8 hours. After receiving at least 9 doses of IV study treatment, participants may be switched to open-label, standard-of-care oral step-down antibiotic therapy at the investigator's discretion. Total antibiotic duration (IV only or IV + oral) is a minimum of 7 days and a maximum of 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Meropenem</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Meropenem 20 mg/kg (maximum 1 g/dose) administered IV every 8 hours. After receiving at least 9 doses of IV study treatment, participants may be switched to open-label, standard-of-care oral step-down antibiotic therapy at the investigator's discretion. Total antibiotic duration (IV only or IV + oral) is a minimum of 7 days and a maximum of 14 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ceftolozane</intervention_name>
    <description>Ceftolozane 20 mg/kg (maximum 1 g/dose) administered IV every 8 hours for between 7 to 14 days</description>
    <arm_group_label>Ceftolozane/Tazobactam</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tazobactam</intervention_name>
    <description>Tazobactam 10 mg/kg (maximum 0.5 g/dose) administered IV every 8 hours for between 7 to 14 days</description>
    <arm_group_label>Ceftolozane/Tazobactam</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Meropenem</intervention_name>
    <description>Meropenem 20 mg/kg (maximum 1 g/dose) administered IV every 8 hours for between 7 to 14 days.</description>
    <arm_group_label>Meropenem</arm_group_label>
    <other_name>MERREM®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Has a legal representative who provides written informed consent on the participant's
             behalf and provides age-appropriate written informed assent (as applicable) for the
             trial.

          -  Ages from birth (defined as &gt;32 weeks gestational age and ≥7 days postnatal) to &lt;18
             years of age.

          -  Requires IV antibacterial therapy for the treatment of cUTI.

          -  Have a pretreatment baseline urine culture specimen obtained within 48 hours before
             the start of administration of the first dose of study treatment and preferably prior
             to administration of any potentially therapeutic antibiotics.

          -  Has pyuria.

          -  Has clinical signs and/or symptoms of cUTI at the Screening Visit.

          -  Is not of reproductive potential; but if of reproductive potential agrees to avoid
             becoming pregnant or impregnating a partner during screening, while receiving study
             treatment and for at least 30 days after the last dose of study treatment.

          -  Female of reproductive potential is not pregnant, and not planning to become pregnant
             within 30 days of the last day of treatment administration; and is nonlactating.

        Exclusion Criteria:

          -  Is currently participating in or has participated in an interventional clinical trial
             with an investigational compound or device within 30 days prior to the first dose of
             study treatment in this current trial.

          -  Has previously participated in any trial of ceftolozane or ceftolozane/tazobactam or
             has enrolled previously in the current trial and been discontinued.

          -  Has a history of any moderate or severe hypersensitivity (eg, anaphylaxis), allergic
             reaction, or other contraindication to any of the following: β-lactam antibiotics (eg,
             penicillins, cephalosporins, and carbapenems), β-lactamase inhibitors (eg, tazobactam,
             sulbactam, clavulanic acid, avibactam), or metronidazole.

          -  Has a history of a cUTI within the past 1 year prior to randomization known to be
             caused by a pathogen resistant to either IV study treatment.

          -  Has a concomitant infection at the time of randomization that requires nonstudy
             systemic antibacterial therapy in addition to IV study treatment or oral step -down
             therapy.

          -  Has received potentially therapeutic antibacterial therapy for a duration more than 24
             hours during the 48 hours preceding the first dose of study treatment.

          -  Has any of the following: a) intractable UTI or pyelonephritis infection at baseline
             that the Investigator anticipates would require more than 14 days of study treatment;
             b) confirmed fungal urinary tract infection at time of randomization; c) permanent
             indwelling bladder catheter or instrumentation including nephrostomy; d) current
             urinary catheter that is not scheduled to be removed before the end of all study
             treatment; e) complete, permanent obstruction of the urinary tract; f) suspected or
             confirmed perinephric or intrarenal abscess; g) documented ileal loop reflux; h)
             suspected or confirmed prostatitis, urethritis, or epididymitis; i) trauma to
             pelvis/urinary tract.

          -  Has moderate or severe impairment of renal function.

          -  Has a seizure disorder or is anticipated to be treated with divalproex sodium or
             valproic acid during the course of study treatment.

          -  Is receiving, or is expected to receive, any prohibited medications.

          -  Has any rapidly progressing disease or immediately life-threatening illness, including
             acute hepatic failure, respiratory failure, or septic shock.

          -  Has an immunocompromising condition.

          -  Has a history of malignancy ≤5 years prior to signing informed consent.

          -  Is planning to receive suppressive/prophylactic antibiotics with gram-negative
             activity after completion of study treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
    <email>Trialsites@merck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Children's Hospital - Los Angeles ( Site 2509)</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Orange County ( Site 2502)</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>714-509-4791</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rady Children's Hospital-San Diego ( Site 2505)</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Ann &amp; Robert H. Lurie Children's Hospital of Chicago ( Site 2519)</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>312-227-6280</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Our Lady of the Lake Hospital ( Site 2512)</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70808</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>St. Louis Children's Hospital ( Site 2508)</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>314-747-5128</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>SUNY Upstate Medical University Hospital ( Site 2510)</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Wake Forest Baptist Health ( Site 2520)</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Baylor College Of Medicine ( Site 2515)</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>832-824-5650</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pan and Aglaia Kyriakou Children s Hospital ( Site 0780)</name>
      <address>
        <city>Athens</city>
        <state>Attiki</state>
        <zip>115 27</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>University of Athens - Aghia Sophia Childrens Hospital ( Site 0730)</name>
      <address>
        <city>Athens</city>
        <state>Attiki</state>
        <zip>115 27</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Athens University Hospital ATTIKON ( Site 0790)</name>
      <address>
        <city>Athens</city>
        <state>Attiki</state>
        <zip>124 62</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>General University Hospital of Larissa ( Site 0740)</name>
      <address>
        <city>Larissa</city>
        <state>Thessalia</state>
        <zip>411 10</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Hippokration General Hospital of Thessaloniki ( Site 0700)</name>
      <address>
        <city>Thessaloniki</city>
        <zip>546 42</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>PTE AOK Klinikai Kozpont ( Site 0809)</name>
      <address>
        <city>Pecs</city>
        <state>Baranya</state>
        <zip>7623</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3672535900</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>SZTE Szent-Gyorgyi Albert Klinikai Kozpont ( Site 0804)</name>
      <address>
        <city>Szeged</city>
        <state>Csongrad</state>
        <zip>6720</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3662545330</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>SzSzBMK es Egyetemi Oktatokorhaz Josa Andras Oktatokorhaz ( Site 0808)</name>
      <address>
        <city>Nyiregyhaza</city>
        <state>Szabolcs-Szatmar-Bereg</state>
        <zip>4400</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+36425997001296</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Semmelweis Egyetem ( Site 0810)</name>
      <address>
        <city>Budapest</city>
        <zip>1083</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+361342858</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Heim Pal Orszagos Gyermekgyogyaszati Intezet ( Site 0801)</name>
      <address>
        <city>Budapest</city>
        <zip>1089</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Debreceni Egyetem Klinikai Kozpont ( Site 0803)</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3652255603</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Civil de Guadalajara Fray Antonio Alcalde ( Site 1202)</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44280</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+523331679113</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto Tecnologico y de Estudios Superiores de Monterrey ( Site 1204)</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo Leon</state>
        <zip>64710</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Pediatria ( Site 1201)</name>
      <address>
        <city>Mexico City</city>
        <zip>04530</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+525510840900</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Infantil de Mexico Federico Gomez ( Site 1203)</name>
      <address>
        <city>Mexico City</city>
        <zip>06720</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+525552289917</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wojewodzki Szpital Obserwacyjno Zakazny ( Site 1606)</name>
      <address>
        <city>Bydgoszcz</city>
        <state>Kujawsko-pomorskie</state>
        <zip>85-030</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48523255605</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Szpital Uniwersytecki nr 1 im. Dr. Antoniego Jurasza w Bydgoszczy ( Site 1600)</name>
      <address>
        <city>Bydgoszcz</city>
        <state>Kujawsko-pomorskie</state>
        <zip>85-094</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Wojewodzki Szpital Zespolony im. Rydgiera ( Site 1607)</name>
      <address>
        <city>Torun</city>
        <state>Kujawsko-pomorskie</state>
        <zip>87-100</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48566794646</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instytut Centrum Zdrowia Matki Polki ( Site 1602)</name>
      <address>
        <city>Lodz</city>
        <state>Lodzkie</state>
        <zip>93-338</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48502651132</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Uniw. Szpital Dzieciecy w Krakowie ( Site 1609)</name>
      <address>
        <city>Krakow</city>
        <state>Malopolskie</state>
        <zip>30-663</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48604787415</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>SPZOZ im. Dzieci Warszawy w Dziekanowie Lesnym ( Site 1608)</name>
      <address>
        <city>Lomianki</city>
        <state>Mazowieckie</state>
        <zip>05-092</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48227657153</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic de Urgenta pentru Copii Maria Sklodowska Curie ( Site 1707)</name>
      <address>
        <city>Bucharest</city>
        <state>Bucuresti</state>
        <zip>041451</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Spit. Cl. de Urg. Copii Cluj Napoca ( Site 1708)</name>
      <address>
        <city>Cluj-Napoca</city>
        <state>Cluj</state>
        <zip>400177</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+40722464526</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic de Urgenta pentru Copii Brasov ( Site 1703)</name>
      <address>
        <city>Brasov</city>
        <zip>500063</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Institutul National de Boli Infectioase Prof. Dr. Matei Bals ( Site 1706)</name>
      <address>
        <city>Bucuresti</city>
        <zip>021106</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+40724354456</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Russian Pediatric Clinical Hospital ( Site 1808)</name>
      <address>
        <city>Moscow</city>
        <state>Moskva</state>
        <zip>119571</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>St.Petersburg State Pediatric Medical University ( Site 1811)</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Sankt-Peterburg</state>
        <zip>194100</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79219536683</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Smolensk Regional Clinical Hospital ( Site 1800)</name>
      <address>
        <city>Smolensk</city>
        <state>Smolenskaya Oblast'</state>
        <zip>214018</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79107896781</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Regional Childrens Clinical Hospital ( Site 1805)</name>
      <address>
        <city>Stavropol</city>
        <state>Stavropol'skiy Kray</state>
        <zip>355029</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79624507653</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sefako Makgatho Health Sciences University ( Site 1903)</name>
      <address>
        <city>Pretoria</city>
        <state>Gauteng</state>
        <zip>0208</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+27125215633</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Inkosi Albert Luthuli Central Hospital ( Site 1902)</name>
      <address>
        <city>Durban</city>
        <state>Kwazulu-Natal</state>
        <zip>4091</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+27837995674</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Red Cross War Memorial Children's Hospital ( Site 1900)</name>
      <address>
        <city>Cape Town</city>
        <state>Western Cape</state>
        <zip>7700</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+27216585369</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cukurova Universitesi Tıp Fakultesi Balcalı Hastanesi ( Site 2200)</name>
      <address>
        <city>Adana</city>
        <zip>01330</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+905326534166</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hacettepe Universitesi Tip Fakultesi Hastanesi ( Site 2201)</name>
      <address>
        <city>Ankara</city>
        <zip>06230</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+905324135130</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Eskisehir Osmangazi Unv. Tip Fakultesi ( Site 2202)</name>
      <address>
        <city>Eskisehir</city>
        <zip>26480</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+905422423608</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>SBU Sariyer Hamidiye Etfal Egitim ve Arastirma Hastanesi ( Site 2203)</name>
      <address>
        <city>Istanbul</city>
        <zip>34453</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+905055803297</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>SI Dnipropetrovsk Regional Children Clinical Hospital DOR ( Site 2402)</name>
      <address>
        <city>Dnipro</city>
        <state>Dnipropetrovska Oblast</state>
        <zip>49100</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380509142649</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>PI Kryvorizka city clinical hospital 8 ( Site 2408)</name>
      <address>
        <city>Kryvyy Rig</city>
        <state>Dnipropetrovska Oblast</state>
        <zip>50082</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380676339039</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ivano-Frankivsk Regional Children Clinical Hospital ( Site 2411)</name>
      <address>
        <city>Ivano-Frankivsk</city>
        <state>Ivano-Frankivska Oblast</state>
        <zip>76014</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380681040592</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Reg. Clinical Center of Urology and Nephrology n.a. V. I. Shapoval ( Site 2410)</name>
      <address>
        <city>Kharkiv</city>
        <state>Kharkivska Oblast</state>
        <zip>61037</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380503434253</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kharkiv City Children Hospital 16 ( Site 2414)</name>
      <address>
        <city>Kharkiv</city>
        <state>Kharkivska Oblast</state>
        <zip>61075</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380662571720</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Children Specialised Hospital OHMADYT MOH Ukraine ( Site 2409)</name>
      <address>
        <city>Kyiv</city>
        <state>Kyivska Oblast</state>
        <zip>01135</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380666668347</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Municipal Institution City Children s Clinical Hospital of Poltava City Council ( Site 2404)</name>
      <address>
        <city>Poltava</city>
        <state>Poltavska Oblast</state>
        <zip>36004</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380509649499</phone>
    </contact>
  </location>
  <location_countries>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Mexico</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>Turkey</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>July 24, 2017</study_first_submitted>
  <study_first_submitted_qc>July 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2017</study_first_posted>
  <last_update_submitted>June 23, 2020</last_update_submitted>
  <last_update_submitted_qc>June 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Urinary Tract Infections</mesh_term>
    <mesh_term>Pyelonephritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meropenem</mesh_term>
    <mesh_term>Tazobactam</mesh_term>
    <mesh_term>Ceftolozane</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

